ImageneBio, Inc.

ImageneBio, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California, dedicated to developing novel therapeutics for patients suffering from immunological, autoimmune, and inflammatory diseases. The company's mission is to globally develop new medicines with differentiated profiles that can effectively control and change the course of these grievous conditions, treating symptoms and improving patients' quality of life.

The company's lead asset is IMG-007, a non-depleting anti-OX40 monoclonal antibody. This investigational therapeutic is designed to specifically bind to the OX40 receptor on activated T cells, thereby blocking its interaction with the OX40 ligand (OX40L) without depleting the T cells. IMG-007 is currently undergoing Phase 2b clinical trials for moderate-to-severe atopic dermatitis, and a Phase 2 study for alopecia areata is planned for 2026, building on completed Phase 1b/2a trials in both indications.

ImageneBio became a publicly traded company on July 28, 2025, following a reverse merger with Ikena Oncology, Inc., and its shares are listed on the NASDAQ Capital Market under the ticker symbol IMA. In April 2026, the company secured a $30 million private placement to further advance the development of IMG-007. Kristin Yarema, Ph.D., serves as the Chief Executive Officer and Director, leading the company's efforts to bring potentially best-in-class treatments to market.